PD36: Bladder Cancer: Invasive V

Podium Session Moderator(s)

• 

  Siamak Daneshmand, MD

  Professor of Urology, Director of Urologic Oncology
  University of Southern California
• 

  Tullika Garg, MD (she/her/hers)

  Associate Professor
  Geisinger Health System
• 

  Debasish Sundi, MD

  Assistant Professor
  The Ohio State University James Cancer Center

Presentations:

• 3:30 PM – 3:40 PM CST

  PD36-01: Nectin-4 protein expression in muscle invasive bladder cancer - selective predictor or consistently expressed in tumor tissue?
  

  Podium Presenter: Sebastian Jersinovic, MD – University Hospital Tuebingen
• 3:40 PM – 3:50 PM CST

  PD36-02: A composite biomarker approach to spare neoadjuvant chemotherapy in select muscle-invasive bladder cancer patients
  

  Podium Presenter: Joep Jacobus De Jong, PhD – Erasmus MC
• 3:50 PM – 4:00 PM CST

  PD36-03: Vesical Imaging Reporting and Data System (VI-RADS) could Predict the Prognosis of Bladder Cancer Patients Received Radical Cystectomy
  

  Podium Presenter: Qiang Lyu, MD
• 4:10 PM – 4:20 PM CST

  PD36-05: Assessment of circulating tumor DNA status as a prognostic marker for recurrence detection in patients with muscle invasive bladder cancer
  

  Podium Presenter: Shivaram Cumarasamy, MD
• 4:20 PM – 4:30 PM CST

  PD36-06: Extramural Venous Invasion: A Novel Magnetic Resonance Imaging Biomarker for Adverse Pathology in Bladder Cancer
  

  Podium Presenter: Allison Feibus, MD,MS
• 4:30 PM – 4:40 PM CST

  PD36-07: Defining optimal candidates for bladder-sparing treatment in muscle-invasive bladder cancer: analysis using pathological reference standards after chemoradiation
  

  Podium Presenter: Hajime Tanaka, MD (he/him/his) – Institute of Science Tokyo
• 4:40 PM – 4:50 PM CST

  PD36-08: Perioperative Outcomes of Radical Cystectomy Following Neoadjuvant Gemcitabine, Cisplatin and Atezolizumab
  

  Podium Presenter: Ali Mouzannar, MD – University of Miami
• 4:50 PM – 5:00 PM CST

  PD36-09: Time trends in systemic treatments and survival in patients with metastatic urothelial bladder cancer: Outcomes in the era of immunotherapy
  

  Podium Presenter: Harshit Garg, MD, M.Ch (he/him/his)
• 5:00 PM – 5:10 PM CST

  PD36-10: Survival differences between primary versus secondary muscle-invasive bladder cancer patients treated with radical cystectomy
  

  Podium Presenter: Mike Wenzel, MD
• 5:10 PM – 5:20 PM CST

  PD36-11: Prospective randomized comparison of perioperative pain control to enhance recovery with Radical Cystectomy
  

  Podium Presenter: Isamu Tachibana, MD – University of Texas Southwestern
• 5:20 PM – 5:30 PM CST

  PD36-12: Measuring objective recovery of activity levels using wearable devices following open vs intracorporeal robotic cystectomy: secondary outcomes analysis of the iROC randomized trial.
  

  Podium Presenter: Pramit Khetrapal, MD,PhD – UCL